Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers
Filename | 152. Türk et al., How to treat patients questions, JACIinPract 2020.pdf |
Filesize | 451,05 kB |
Version | r.152 |
Date added | Juni 17, 2019 |
Downloaded | 11 times |
Category | Reviews |
Tags | angioedema, chronic spontaneous urticaria, Disease response, omalizumab, treatment, Wheals |
Authors | Türk, M., Carneiro-Leão, L., Kolkhir, P., Bonnekoh, H., Buttgereit, T., and Maurer, M. |
Citation | Türk, M., Carneiro-Leão, L., Kolkhir, P., Bonnekoh, H., Buttgereit, T., and Maurer, M.+: How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J. Allergy Clin. Immunol. Pract. 2020: 8; 115-124. |
Corresponding authors | Maurer, M. |
DocNum | r.152 |
DocType | |
Edition; Page | 8; 115-124 |
IF | 8.86 |
Publisher | J. Allergy Clin. Immunol. Pract. |
ReleaseDate | 2020 |
Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU). In routine clinical practice, physicians often face complex cases of CSU and need to decide whether patients are suitable for omalizumab treatment and how to manage this therapy. Here, we provide evidence and experience-based answers to the most common and important questions on omalizumab treatment of CSU. At 4 large urticaria centers, questions on the use of omalizumab in the treatment of patients with CSU were collected and then ranked by frequency and importance and grouped into top 5 domains using an interactive consensus approach. We suggest that omalizumab can be used to treat patients with CSU with any of the 3 CSU phenotypes (wheals only, angioedema only, wheals and angioedema), with comorbid chronic inducible urticaria, with cancer, who receive other biologics or cyclosporine, or who are pregnant or want to become pregnant, or are breast-feeding. Omalizumab treatment should be started with 300 mg every 4 weeks, monitored with validated patient-reported outcome measures, and maintained, in responders, until remission of CSU. Finally, partial responders or non responders can benefit from omalizumab updosing or adding or switching to cyclosporine. We believe our suggestions on the use of omalizumab in CSU will help to inform clinical decision making. Follow-up efforts should increase, systematically review, and profile the data available and provide evidence-based recommendations on how to best use omalizumab in
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.